CytomX Gross Profit from 2010 to 2025

CTMX Stock

USD 0.67 0 0.45%

CytomX Therapeutics Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit is likely to outpace its year average in 2025. Gross Profit is the profit CytomX Therapeutics makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2013-12-31

Previous Quarter

33.4 M

Current Value

38.1 M

Quarterly Volatility

12 M

Yuan Drop

Covid

Check CytomX Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CytomX Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.3 M, Interest Expense of 2.1 M or Selling General Administrative of 29.1 M, as well as many indicators such as Price To Sales Ratio of 0.6, Dividend Yield of 0.0299 or Days Sales Outstanding of 7.79. CytomX financial statements analysis is a perfect complement when working with CytomX Therapeutics Valuation or Volatility modules.

Check out the analysis of CytomX Therapeutics Correlation against competitors.

For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.

Latest CytomX Therapeutics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of CytomX Therapeutics over the last few years. Gross profit is a required income statement account that reflects total revenue of CytomX Therapeutics minus its cost of goods sold. It is profit before CytomX Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. CytomX Therapeutics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CytomX Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 138.1 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

CytomX Gross Profit Regression Statistics

	Arithmetic Mean	51,713,822
	Geometric Mean	17,351,481
	Coefficient Of Variation	96.79
	Mean Deviation	41,326,594
	Median	57,489,000
	Standard Deviation	50,056,121
	Sample Variance	2505.6T
	Range	144.1M
	R-Value	0.92
	Mean Square Error	431.6T
	R-Squared	0.84
	Slope	9,631,761
	Total Sum of Squares	37584.2T

CytomX Gross Profit History

	2025	145 M
	2024	138.1 M
	2023	101.2 M
	2022	53.2 M
	2021	69.6 M
	2020	100.4 M
	2019	57.5 M

Other Fundumenentals of CytomX Therapeutics

Gross Profit Margin

CytomX Therapeutics Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Good Will	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Net Tangible Assets	Deferred Long Term Liab	Short Long Term Debt	Capital Surpluse	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.69	0.52	-0.92	-0.41	0.7	0.18	0.19	0.87	0.85	1.0	0.56	-0.31	0.19	0.42	0.84	0.66	0.19	0.42	0.1	-0.06	0.19
Total Stockholder Equity	0.69		-0.04	-0.6	0.01	0.77	-0.33	0.07	0.64	0.28	0.71	0.76	0.08	0.07	0.23	0.91	0.24	0.07	0.02	0.54	0.26	0.07
Current Deferred Revenue	0.52	-0.04		-0.37	-0.93	0.04	0.54	-0.15	0.6	0.74	0.49	0.03	-0.89	-0.15	0.26	0.31	0.81	-0.15	0.88	-0.72	-0.79	-0.15
Net Debt	-0.92	-0.6	-0.37		0.27	-0.69	-0.29	-0.26	-0.66	-0.8	-0.92	-0.46	0.16	-0.26	-0.36	-0.73	-0.52	-0.26	-0.31	-0.2	-0.1	-0.26
Retained Earnings	-0.41	0.01	-0.93	0.27		0.05	-0.45	0.46	-0.52	-0.64	-0.38	0.01	0.97	0.46	-0.33	-0.3	-0.88	0.46	-0.95	0.72	0.93	0.46
Accounts Payable	0.7	0.77	0.04	-0.69	0.05		0.05	0.33	0.58	0.37	0.71	0.82	0.19	0.33	0.26	0.83	0.09	0.33	-0.09	0.31	0.33	0.33
Net Receivables	0.18	-0.33	0.54	-0.29	-0.45	0.05		-0.02	0.2	0.47	0.18	0.05	-0.37	-0.02	-0.05	0.01	0.32	-0.02	0.35	-0.7	-0.39	-0.02
Good Will	0.19	0.07	-0.15	-0.26	0.46	0.33	-0.02		-0.06	-0.03	0.2	0.04	0.43	1.0	-0.07	0.06	-0.44	1.0	-0.32	0.32	0.62	1.0
Short Term Investments	0.87	0.64	0.6	-0.66	-0.52	0.58	0.2	-0.06		0.78	0.88	0.7	-0.4	-0.06	0.28	0.83	0.7	-0.06	0.43	-0.11	-0.26	-0.06
Total Liab	0.85	0.28	0.74	-0.8	-0.64	0.37	0.47	-0.03	0.78		0.84	0.26	-0.52	-0.03	0.43	0.53	0.82	-0.03	0.58	-0.27	-0.37	-0.03
Total Current Assets	1.0	0.71	0.49	-0.92	-0.38	0.71	0.18	0.2	0.88	0.84		0.6	-0.28	0.2	0.38	0.85	0.64	0.2	0.39	0.13	-0.03	0.2
Short Term Debt	0.56	0.76	0.03	-0.46	0.01	0.82	0.05	0.04	0.7	0.26	0.6		0.12	0.04	-0.07	0.8	0.15	0.04	-0.09	0.24	0.2	0.04
Intangible Assets	-0.31	0.08	-0.89	0.16	0.97	0.19	-0.37	0.43	-0.4	-0.52	-0.28	0.12		0.43	-0.27	-0.19	-0.83	0.43	-0.98	0.7	0.93	0.43
Common Stock	0.19	0.07	-0.15	-0.26	0.46	0.33	-0.02	1.0	-0.06	-0.03	0.2	0.04	0.43		-0.07	0.06	-0.44	1.0	-0.32	0.32	0.62	1.0
Property Plant Equipment	0.42	0.23	0.26	-0.36	-0.33	0.26	-0.05	-0.07	0.28	0.43	0.38	-0.07	-0.27	-0.07		0.28	0.45	-0.07	0.32	-0.09	-0.24	-0.07
Net Tangible Assets	0.84	0.91	0.31	-0.73	-0.3	0.83	0.01	0.06	0.83	0.53	0.85	0.8	-0.19	0.06	0.28		0.45	0.06	0.29	0.2	0.0	0.06
Deferred Long Term Liab	0.66	0.24	0.81	-0.52	-0.88	0.09	0.32	-0.44	0.7	0.82	0.64	0.15	-0.83	-0.44	0.45	0.45		-0.44	0.85	-0.42	-0.72	-0.44
Short Long Term Debt	0.19	0.07	-0.15	-0.26	0.46	0.33	-0.02	1.0	-0.06	-0.03	0.2	0.04	0.43	1.0	-0.07	0.06	-0.44		-0.32	0.32	0.62	1.0
Capital Surpluse	0.42	0.02	0.88	-0.31	-0.95	-0.09	0.35	-0.32	0.43	0.58	0.39	-0.09	-0.98	-0.32	0.32	0.29	0.85	-0.32		-0.59	-0.84	-0.32
Net Invested Capital	0.1	0.54	-0.72	-0.2	0.72	0.31	-0.7	0.32	-0.11	-0.27	0.13	0.24	0.7	0.32	-0.09	0.2	-0.42	0.32	-0.59		0.83	0.32
Net Working Capital	-0.06	0.26	-0.79	-0.1	0.93	0.33	-0.39	0.62	-0.26	-0.37	-0.03	0.2	0.93	0.62	-0.24	0.0	-0.72	0.62	-0.84	0.83		0.62
Capital Stock	0.19	0.07	-0.15	-0.26	0.46	0.33	-0.02	1.0	-0.06	-0.03	0.2	0.04	0.43	1.0	-0.07	0.06	-0.44	1.0	-0.32	0.32	0.62

Click cells to compare fundamentals

About CytomX Therapeutics Financial Statements

CytomX Therapeutics investors use historical fundamental indicators, such as CytomX Therapeutics' Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in CytomX Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	138.1 M	145 M
Gross Profit Margin	1.02	0.99

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for CytomX Stock Analysis

When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC